# Tesamorelin vs Sermorelin: What the Research Distinguishes > Tesamorelin vs sermorelin: a structural comparison the literature supports — full-length stabilized GHRH(1-44) with DPP-IV resistance versus truncated GHRH(1-29). Not a head-to-head efficacy claim. Both are GHRH analogues. The difference is structural — chain length and a stabilizing modification — and the literature supports a structural comparison, not a head-to-head efficacy verdict. ## The short version Tesamorelin vs sermorelin comes down to two design choices. Both are lab-made versions of GHRH (the brain's own "make growth hormone" signal), and both nudge the pituitary gland to release the body's own growth hormone. The differences: tesamorelin copies the full natural hormone (all 44 amino acids) and adds a chemical cap that stops it from being broken down quickly; sermorelin uses a shorter fragment (the first 29 amino acids) and has no such cap. One has been through large FDA-approval trials for a specific HIV condition; the other has a different and older regulatory history. This page compares the chemistry, not which one "wins" — no trial has ever put them head-to-head. ## The structural difference: full-length and stabilized vs truncated Tesamorelin is a full-length GHRH(1-44) analogue — it reproduces the complete 44-amino-acid sequence of human growth hormone-releasing hormone and adds a trans-3-hexenoic acid group on the N-terminus. Sermorelin is GHRH(1-29): a truncated fragment comprising only the first 29 amino acids, which is the minimum sequence retaining GH-releasing activity. The two molecules therefore start from different lengths of the same parent hormone. The stabilizing modification is the second axis of difference. Tesamorelin's N-terminal trans-3-hexenoic acid group confers resistance to DPP-IV — the protease that rapidly inactivates native GHRH. Sermorelin carries no such modification. That is the chemistry the comparison rests on: tesamorelin is built both longer and tougher. It is worth stating the comparison precisely rather than loosely. Three axes separate the two: chain length (44 amino acids versus 29), the presence or absence of an N-terminal stabilizing group (present in tesamorelin, absent in sermorelin), and the resulting susceptibility to DPP-IV (resistant versus not). Tesamorelin carries the CAS identifier 218949-48-5 and a molecular weight of 5,135.9 Da, reflecting both the longer sequence and the added fatty-acid group. None of these structural facts, on their own, predicts a clinical outcome — they describe how each molecule is built, which is the honest scope of a structural comparison. ## Why DPP-IV resistance matters mechanically Native GHRH is cleaved by DPP-IV within minutes, which limits how long any unmodified GHRH-based molecule can signal. Tesamorelin's N-terminal modification blocks that cleavage, extending its biological activity relative to native GHRH. Mechanically, this means a stabilized GHRH analogue can keep engaging the GHRH receptor longer than the unprotected sequence would — and in healthy men, tesamorelin demonstrably augmented endogenous pulsatile GH release over a two-week course [6]. This is a mechanistic and pharmacologic distinction drawn from the structure, not a claim that one analogue outperforms the other in a clinical endpoint. No randomized trial has compared tesamorelin and sermorelin head-to-head, so any efficacy ranking would be an inference beyond the published evidence. What the literature does support is the structural reading: full-length and DPP-IV-resistant on one side, truncated and unmodified on the other. ## Different evidence bases and regulatory frames The two compounds also differ in what has been studied and approved. Tesamorelin carries an unusually deep human evidence base for its class — two pivotal Phase 3 RCTs in HIV-associated lipodystrophy [1][2], an earlier dose-ranging trial [7], a JAMA liver-fat trial [3], dedicated PK and PK/PD analyses [8][9], and a 2026 meta-analysis [12] — and is FDA-approved (NDA 022505, 2010) solely for reducing excess abdominal fat in HIV patients with lipodystrophy [5]. Sermorelin has a separate, older regulatory and research history not covered by this digest. For tesamorelin, the approval scope is the load-bearing fact: approved for HIV-associated lipodystrophy, off-label for everything else [5]. A structural similarity to another GHRH analogue does not transfer any approval or efficacy claim between them. Both raise the body's own GH by the same broad mechanism; the differences this page documents are chain length, stabilization, and the evidence each has accumulated. Notably, anti-doping science treats them as a family: a 2026 urine assay was validated to screen sermorelin, tesamorelin, and related GHRH analogues together [13]. --- One lamp on the tesamorelin record — the minutes-long plasma clearance and the day-long IGF-1 afterglow read straight from the studies and cited to source, with no clinic behind the candle and nothing here dispensed, priced, or sold.